For research use only. Not for therapeutic Use.
AD57 is an orally active multikinase inhibitor, inhibits RET, BRAF, S6K and Src, with greatly reduces mTOR activity[1].
AD57 (0.2 nM) significantly inhibits the ptc > dRetMEN2B lethality in the larva of Drosophila[1].
AD57 (0.1 nM) enhances survival of ptc > dRetMEN2B by reducing erk gene dosage in Drosophila[1].
AD57 inhibits the viability of MEN2B (MZ-CRC-1) and MEN2A (TT) patient-derived cell lines in RETMEN2 models[1].
AD57 (20 mg/kg) significantly inhibits TT-based tumour growth without obvious cytotoxicity in conventional mouse xenograft model[1].
| Catalog Number | I041687 |
| CAS Number | 1093380-42-7 |
| Synonyms | 1-[4-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)phenyl]-3-[3-(trifluoromethyl)phenyl]urea |
| Molecular Formula | C22H20F3N7O |
| Purity | ≥95% |
| InChI | InChI=1S/C22H20F3N7O/c1-12(2)32-20-17(19(26)27-11-28-20)18(31-32)13-6-8-15(9-7-13)29-21(33)30-16-5-3-4-14(10-16)22(23,24)25/h3-12H,1-2H3,(H2,26,27,28)(H2,29,30,33) |
| InChIKey | LEERPLGXOHLQPF-UHFFFAOYSA-N |
| SMILES | CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC=C(C=C3)NC(=O)NC4=CC=CC(=C4)C(F)(F)F)N |
| Reference | [1]. Dar AC, et al. Chemical genetic discovery of targets and anti-targets for cancer polypharmacology. Nature. 2012 Jun 6;486(7401):80-4. |
